SDSunil Deshpande

Sunil Deshpande

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sunil Deshpande has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Glucose Rate-of-Change and Insulin-on-Board Jointly Weighted Zone Model Predictive Control

    by Sunil Deshpande, Francis J. Doyle, Eyal Dassau

    We present the design and evaluation of closed-loop insulin delivery using zone model predictive control (MPC) featuring an adaptive weighting scheme to address prolonged hyperglycemia due to changes in insulin sensitivity, underdelivery from profile mismatch, and meal composition. In the MPC cost function, the penalty on predicted glucose deviation from the upper zone boundary is weighted by a joint function of predicted glucose rate-of-change (ROC) and insulin-on-board (IOB). The asymmetric weighting gradually increases when glucose ROC and IOB are jointly low, independent of glucose magnitude, to limit hyperglycemia, while aggressively reducing for negative glucose ROC to avoid hypoglycemia. The proposed controller was evaluated using two simulation scenarios: an induced resistance scenario and a nominal scenario to highlight the performance over a reference zone MPC with glucose ROC weighting only. The continuous adaption scheme resulted in consistent improvement for the entire glucose range without incurring an additional risk of hypoglycemia. For the induced resistance and no feedforward bolus scenario, the percent time in 70–180 mg/dL was higher (53.5% versus 48.9%, $p < 0.001$ ) with a larger improvement in the overnight percent time in the tighter glucose range 70–140 mg/dL (70.9% versus 52.9%, $p < 0.001$ ). The results from extensive simulations, as well as clinical validation in three different outpatient studies, demonstrate the utility and safety of the proposed zone MPC.


  • Outpatient Randomized Crossover Comparison of Zone Model Predictive Control Automated Insulin Delivery with Weekly Data Driven Adaptation Versus Sensor-Augmented Pump: Results from the International Diabetes Closed-Loop Trial 4

    by Jordan E Pinsker, Eyal Dassau, Sunil Deshpande, Dan Raghinaru, Bruce A Buckingham, Yogish C Kudva, Lori M Laffel, Carol J Levy, Mei Mei Church, Hannah Desrochers, et al.

    Background: Automated insulin delivery (AID) systems have proven effective in increasing time-in-range during both clinical trials and real-world use. Further improvements in outcomes for single-hormone (insulin only) AID may be limited by suboptimal insulin delivery settings. Methods: Adults (≥18 years of age) with type 1 diabetes were randomized to either sensor-augmented pump (SAP) (inclusive of predictive low-glucose suspend) or adaptive zone model predictive control AID for 13 weeks, then crossed over to the other arm. Each week, the AID insulin delivery settings were sequentially and automatically updated by an adaptation system running on the study phone. Primary outcome was sensor glucose time-in-range 70–180 mg/dL, with noninferiority in percent time below 54 mg/dL as a hierarchical outcome. Results: Thirty-five participants completed the trial (mean age 39 ± 16 years, HbA1c at enrollment 6.9% ± 1.0%). Mean time-in-range 70–180 mg/dL was 66% with SAP versus 69% with AID (mean adjusted difference +2% [95% confidence interval: −1% to +6%], P = 0.22). Median time P = 0.002). The adaptation system decreased initial basal rates by a median of 4% (−8%, 16%) and increased initial carbohydrate ratios by a median of 45% (32%, 59%) after 13 weeks. Conclusions: Automated adaptation of insulin delivery settings with AID use did not significantly improve time-in-range in this very well-controlled population. Additional study and further refinement of the adaptation system are needed, especially in populations with differing degrees of baseline glycemic control, who may show larger benefits from adaptation.


  • Feasibility and Preliminary Safety of Smartphone-Based Automated Insulin Delivery in Adolescents and Children With Type 1 Diabetes

    by Sunil Deshpande, Stuart A. Weinzimer, Kathryn Gibbons, Laura M. Nally, Kate Weyman, Lori Carria, Melinda Zgorski, Lori M. Laffel, Francis J. Doyle, Eyal Dassau

    Background: A smartphone-based automated insulin delivery (AID) controller device can facilitate use of interoperable components and acceptance in adolescents and children. Methods: Pediatric participants (N = 20, 8F) with type 1 diabetes were enrolled in three sequential age-based cohorts: adolescents (12-<18 years, n = 8, 5F), school-age (8-<12 years, n = 7, 2F), and young children (2-<8 years, n = 5, 1F). Participants used the interoperable artificial pancreas system (iAPS) and zone model predictive control (MPC) on an unlocked smartphone for 48 hours, consumed unrestricted meals of their choice, and engaged in various unannounced exercises. Primary outcomes and stopping criteria were defined using fingerstick blood glucose (BG) data; secondary outcomes compared continuous glucose monitoring (CGM) data with preceding sensor augmented pump (SAP) therapy. Results: During AID, there was no more than one BG <50 mg/dL except in one young child participant; no instance of more than two episodes of BG ≥300 mg/dL lasting longer than 2 hours; and no adverse events. Despite large meals (total of 404.9 grams of carbs) and unannounced exercise (total of 182 minutes), overall CGM percent time in range (TIR) of 70 to 180 mg/dL during AID was statistically similar to SAP (63.5% vs 57.3%, respectively, P = .145). Overnight glucose standard deviation was 43 mg/dL (vs SAP 57.9 mg/dL, P = .009) and coefficient of variation was 25.7% (vs SAP 34.9%, P < .001). The percent time in closed-loop mode and connected to the CGM was 92.7% and 99.6%, respectively. Surveys indicated that participants and parents/guardians were satisfied with the system. Conclusions: The smartphone-based AID was feasible and safe in sequentially younger cohorts of adolescents and children. ClinicalTrials.gov: NCT04255381 ( https://clinicaltrials.gov/ct2/show/NCT04255381 )


  • Optimizing behavioral interventions to regulate gestational weight gain with sequential decision policies using hybrid model predictive control

    by Penghong Guo, Daniel E. Rivera, Yuwen Dong, Sunil Deshpande, Jennifer S. Savage, Emily E. Hohman, Abigail M. Pauley, Krista S. Leonard, Danielle Symons Downs


  • Open Access

    Review of automated insulin delivery systems for individuals with type 1 diabetes: tailored solutions for subpopulations

    by Eleonora M. Aiello, Sunil Deshpande, Başak Özaslan, Kelilah L. Wolkowicz, Eyal Dassau, Jordan E. Pinsker, Francis J. Doyle


  • Using Iterative Learning for Insulin Dosage Optimization in Multiple-Daily-Injections Therapy for People With Type 1 Diabetes

    by Marzia Cescon, Sunil Deshpande, Revital Nimri, Francis J. Doyle Iii, Eyal Dassau

    In this work, we design iterative algorithms for the delivery of long-acting (basal) and rapid-acting (bolus) insulin, respectively, for people with type 1 diabetes (T1D) on multiple-daily-injections (MDIs) therapy using feedback from self-monitoring of blood glucose (SMBG) measurements. Iterative learning control (ILC) updates basal therapy consisting of one long-acting insulin injection per day, while run-to-run (R2R) adapts meal bolus therapy via the update of the mealtime-specific insulin-to-carbohydrate ratio (CR). Updates are due weekly and are based upon sparse SMBG measurements. Upon termination of the 20 weeks long in-silico trial, in a scenario characterized by meal carbohydrate (CHO) normally distributed with mean μ = [50, 75, 75] grams and standard deviation σ = [5, 7, 7] grams, our strategy produced statistically significant improvements in time in range (70--180) [mg/dl], from 66.9(33.1) % to 93.6(6.7) %, p = 0.02. Iterative learning shows potential to improve glycemic regulation over time by driving blood glucose closer to the recommended glycemic targets. Decision support systems (DSSs) and automated therapy advisors such as the one proposed here are expected to improve glycemic outcomes reducing the burden on patients on MDI therapy.


  • Design and Clinical Evaluation of the Interoperable Artificial Pancreas System (iAPS) Smartphone App: Interoperable Components with Modular Design for Progressive Artificial Pancreas Research and Development

    by Sunil Deshpande, Jordan E. Pinsker, Stamatina Zavitsanou, Dawei Shi, Randy Tompot, Mei Mei Church, Camille Andre, Francis J. Doyle, Eyal Dassau

    Background: There is an unmet need for a modular artificial pancreas (AP) system for clinical trials within the existing regulatory framework to further AP research projects from both academia and industry. We designed, developed, and tested the interoperable artificial pancreas system (iAPS) smartphone app that can interface wirelessly with leading continuous glucose monitors (CGM), insulin pump devices, and decision-making algorithms while running on an unlocked smartphone. Methods: After algorithm verification, hazard and mitigation analysis, and complete system verification of iAPS, six adults with type 1 diabetes completed 1 week of sensor-augmented pump (SAP) use followed by 48 h of AP use with the iAPS, a Dexcom G5 CGM, and either a Tandem or Insulet insulin pump in an investigational device exemption study. The AP system was challenged by participants performing extensive walking without exercise announcement to the controller, multiple large meals eaten out at restaurants, two overnight periods, and multiple intentional connectivity interruptions. Results: Even with these intentional challenges, comparison of the SAP phase with the AP study showed a trend toward improved time in target glucose range 70–180 mg/dL (78.8% vs. 83.1%; P = 0.31), and a statistically significant reduction in time below 70 mg/dL (6.1% vs. 2.2%; P = 0.03). The iAPS system performed reliably and showed robust connectivity with the peripheral devices (99.8% time connected to CGM and 94.3% time in closed loop) while requiring limited user intervention. Conclusions: The iAPS system was safe and effective in regulating glucose levels under challenging conditions and is suitable for use in unconstrained environments.


  • Control Systems Engineering for Optimizing Behavioral mHealth Interventions

    by Daniel E. Rivera, César A. Martín, Kevin P. Timms, Sunil Deshpande, Naresh N. Nandola, Eric B. Hekler


  • Open Access

    Application of Zone Model Predictive Control Artificial Pancreas During Extended Use of Infusion Set and Sensor: A Randomized Crossover-Controlled Home-Use Trial

    by Gregory P. Forlenza, Sunil Deshpande, Trang T. Ly, Daniel P. Howsmon, Faye Cameron, Nihat Baysal, Eric Mauritzen, Tatiana Marcal, Lindsey Towers, B. Wayne Bequette, et al.

    OBJECTIVE: As artificial pancreas (AP) becomes standard of care, consideration of extended use of insulin infusion sets (IIS) and continuous glucose monitors (CGMs) becomes vital. We conducted an outpatient randomized crossover study to test the safety and efficacy of a zone model predictive control (zone-MPC)–based AP system versus sensor augmented pump (SAP) therapy in which IIS and CGM failures were provoked via extended wear to 7 and 21 days, respectively. RESEARCH DESIGN AND METHODS: A smartphone-based AP system was used by 19 adults (median age 23 years [IQR 10], mean 8.0 ± 1.7% HbA1c) over 2 weeks and compared with SAP therapy for 2 weeks in a crossover, unblinded outpatient study with remote monitoring in both study arms. RESULTS: AP improved percent time 70–140 mg/dL (48.1 vs. 39.2%; P = 0.016) and time 70–180 mg/dL (71.6 vs. 65.2%; P = 0.008) and decreased median glucose (141 vs. 153 mg/dL; P = 0.036) and glycemic variability (SD 52 vs. 55 mg/dL; P = 0.044) while decreasing percent time <70 mg/dL (1.3 vs. 2.7%; P = 0.001). AP also improved overnight control, as measured by mean glucose at 0600 h (140 vs. 158 mg/dL; P = 0.02). IIS failures (1.26 ± 1.44 vs. 0.78 ± 0.78 events; P = 0.13) and sensor failures (0.84 ± 0.6 vs. 1.1 ± 0.73 events; P = 0.25) were similar between AP and SAP arms. Higher percent time in closed loop was associated with better glycemic outcomes. CONCLUSIONS: Zone-MPC significantly and safely improved glycemic control in a home-use environment despite prolonged CGM and IIS wear. This project represents the first home-use AP study attempting to provoke and detect component failure while successfully maintaining safety and effective glucose control.


  • A system identification approach for improving behavioral interventions based on Social Cognitive Theory

    by Cesar A. Martin, Sunil Deshpande, Eric B. Hekler, Daniel E. Rivera

    Mobile and wireless health (mHealth) interventions offer the opportunity for applying control engineering and system identification concepts in behavioral change settings. Social Cognitive Theory provides a recognized theoretical framework that can be applied to explain changes in behavior over time. Based on earlier work describing a dynamical model of this theory, a semi-physical system identification approach is developed in this paper for interventions associated with improving physical activity. An initial informative experiment that relies on prior knowledge from similar interventions is first designed to obtain basic insights regarding the dynamics of the system. Based on these results a second, optimized experiment is developed which solves a constrained optimization problem to find the intervention component profiles needed to mirror a desired behavioral pattern and to provide sufficient information that allows a more precise estimation of the parameters. A simulation study is presented to illustrate the design procedure.